Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Prendergast

Showing results (171-180 of 225) with videos related to

Pageof 23
Sort By:
Biochemistry|May 18, 1993
Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferasesC A Omer, A M Kral, R E Diehl, et al.
Journal for Immunotherapy of Cancer|May 30, 2025
Neovascular pruning by IDO1 inhibitors can potentiate immunogenic cytotoxicity of ischemia-targeted agents to synergistically enhance anti-PD-1 responsivenessShih-Chun Shen, Souvik Dey, James B DuHadaway, et al.
Molecular and Cellular Biology|June 1, 1994
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeletonG C Prendergast, J P Davide, S J deSolms, et al.
Currents in Pharmacy Teaching & Learning|September 7, 2024
Building Interprofessional Educational Bridges internationally: A reflection on our international partnership to equip future healthcare professionals with skills to care for rural and marginalized populationsDevin L Lavender, Virginia Fleming, Blake R Johnson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 14, 2016
Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nauseaThomas Kutner, Emily Kunkel, Yue Wang, et al.
Developmental Cell|December 2, 2004
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membraneEmma Sandilands, Christophe Cans, Valerie J Fincham, et al.
Journal of Medicinal Chemistry|March 6, 2008
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitorsSanjeev Kumar, William P Malachowski, James B DuHadaway, et al.
Cancer Research|January 20, 2007
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responsesDe-Yan Hou, Alexander J Muller, Madhav D Sharma, et al.
Cancer Immunology Research|February 24, 2021
IDO1 Signaling through GCN2 in a Subpopulation of Gr-1<sup>+</sup> Cells Shifts the IFNγ/IL6 Balance to Promote NeovascularizationSouvik Dey, Arpita Mondal, James B DuHadaway, et al.
Oncogene|November 21, 2007
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenaseT Banerjee, J B Duhadaway, P Gaspari, et al.
Pageof 23

Showing results (171-180 of 225) with videos related to

Sort By:
Pageof 23
Biochemistry|May 18, 1993
Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferasesC A Omer, A M Kral, R E Diehl, et al.
Journal for Immunotherapy of Cancer|May 30, 2025
Neovascular pruning by IDO1 inhibitors can potentiate immunogenic cytotoxicity of ischemia-targeted agents to synergistically enhance anti-PD-1 responsivenessShih-Chun Shen, Souvik Dey, James B DuHadaway, et al.
Molecular and Cellular Biology|June 1, 1994
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeletonG C Prendergast, J P Davide, S J deSolms, et al.
Currents in Pharmacy Teaching & Learning|September 7, 2024
Building Interprofessional Educational Bridges internationally: A reflection on our international partnership to equip future healthcare professionals with skills to care for rural and marginalized populationsDevin L Lavender, Virginia Fleming, Blake R Johnson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 14, 2016
Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nauseaThomas Kutner, Emily Kunkel, Yue Wang, et al.
Developmental Cell|December 2, 2004
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membraneEmma Sandilands, Christophe Cans, Valerie J Fincham, et al.
Journal of Medicinal Chemistry|March 6, 2008
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitorsSanjeev Kumar, William P Malachowski, James B DuHadaway, et al.
Cancer Research|January 20, 2007
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responsesDe-Yan Hou, Alexander J Muller, Madhav D Sharma, et al.
Cancer Immunology Research|February 24, 2021
IDO1 Signaling through GCN2 in a Subpopulation of Gr-1<sup>+</sup> Cells Shifts the IFNγ/IL6 Balance to Promote NeovascularizationSouvik Dey, Arpita Mondal, James B DuHadaway, et al.
Oncogene|November 21, 2007
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenaseT Banerjee, J B Duhadaway, P Gaspari, et al.
Pageof 23